The Methodist Hospital Research Institute clinical trial pipeline

8 trials changed in the last 30 days: 0 stopped, 6 with notable changes, 2 with minor changes only.

1. Notable

   Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

   Primary completion pushed from Aug 2026 to Aug 2027

   Also in this update: Study completion pushed from Aug 2027 to Aug 2028

   The Methodist Hospital Research Institute·Phase 1· NCT06566443· Registry history of NCT06566443 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

2. Notable

   5-Fluorouracil (5FU) -Based Therapy in Combination With…5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) · Advanced or Metastatic Colorectal Cancer

   Primary completion pushed from Jun 1, 2026 to Jun 1, 2028

   Also in this update: Study completion pushed from Dec 1, 2027 to Dec 1, 2028

   The Methodist Hospital Research Institute·Phase 1· NCT06833866· Registry history of NCT06833866 on ClinicalTrials.gov (opens the registry)

   Oct 7, 2026

3. Notable

   NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as…NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment · Advanced Small Intestine and Appendiceal Cancers

   Primary completion pushed from Sep 30, 2026 to Sep 30, 2028

   Also in this update: Recruitment opened; Study completion pushed from Dec 31, 2026 to Dec 31, 2029

   The Methodist Hospital Research Institute·Phase 1· NCT07060014· Registry history of NCT07060014 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

4. Notable

   Personalized Transcranial Direct Current Stimulation in Stroke…Personalized Transcranial Direct Current Stimulation in Stroke Recovery

   Primary completion pushed from Mar 14, 2027 to Dec 30, 2028

   Also in this update: Primary endpoint(s) modified; Study completion pushed from Sep 14, 2027 to Sep 30, 2029

   The Methodist Hospital Research Institute·Not applicable· NCT06286800· Registry history of NCT06286800 on ClinicalTrials.gov (opens the registry)

   Sep 21, 2026

5. Notable

   Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

   Primary endpoint(s) modified

   The Methodist Hospital Research Institute·Phase 1/2· NCT07651319· Registry history of NCT07651319 on ClinicalTrials.gov (opens the registry)

   Sep 23, 2026

6. Notable

   Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid…Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

   Recruitment opened

   The Methodist Hospital Research Institute·Phase 2· NCT07060001· Registry history of NCT07060001 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.